ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company, announced on July 3, 2025, the issuance of inducement grants to a new non-executive employee, effective from July 1, 2025. As part of the compensation package, the employee received 9,000 non-qualified stock options and 1,600 restricted stock units, approved by ORIC's Compensation Committee under Nasdaq Rule 5635(c)(4). The stock options have an exercise price set at the closing price of ORIC's common stock on the grant date. Vesting terms for the stock options include 25% vesting after one year and the remainder vesting monthly over the following three years, while the restricted stock units vest in equal parts over three years. These grants were made under the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.